Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial

INTRODUCTION: The prognosis of patients with advanced metastatic colorectal adenocarcinoma (mCRC) after multiple-line therapy remains poor due to the high tumour load, high level of malignancy and strong drug resistance. The application of programmed cell death protein 1 (PD-1) blockade alone for pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Qian, Diao, Yanwen, Sun, Xin, Zhou, Yang, Ran, Jialing, Zhang, Jingdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981335/
https://www.ncbi.nlm.nih.gov/pubmed/35379611
http://dx.doi.org/10.1136/bmjopen-2021-049992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981335/
https://www.ncbi.nlm.nih.gov/pubmed/35379611
http://dx.doi.org/10.1136/bmjopen-2021-049992

Ejemplares similares